Hemab Therapeutics Holdings, Inc.
- COAG ยท Nasdaq
- Biological Products, (No Diagnostic Substances)
- Cambridge, MA
- CIK 0002114044
Updated from SEC filings through
Top things to know
Next earningsJanuary 31, 2027Estimated from past filings
Latest 8-KResults of operations and financial conditionFiled November 10, 2026Leadership changeItem 5.02 filedSeptember 24, 2026, last 90 days Executives
- Catherine Madigan Chief Medical Officer Form 4, May 4, 2026
- Ananthram Sreenivasa Murthy Chief Operating Officer Form 3, April 30, 2026
Hemab Therapeutics Holdings, Inc. is a U.S. public company in biological products, (no diagnostic substances) (SIC 2836), headquartered in Cambridge, MA. It trades as COAG on Nasdaq.
Five-year financials
We have no annual financials for this company yet.
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Catherine Madigan | Chief Medical Officer | Form 4, May 4, 2026 |
| Ananthram Sreenivasa Murthy | Chief Operating Officer | Form 3, April 30, 2026 |
What Hemab Therapeutics Holdings, Inc. does
Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders.
Company website description, 10-K for the year ending November 7, 2026
Shares and governance
| Shares outstanding | 46.7 million (as of October 30, 2026) | 10-Q, November 10, 2026 |
|---|---|---|
| Reportable segments | 1 (period ending September 30, 2026) | 10-Q, November 10, 2026 |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| May 6, 2026 | Peter Kolchinsky Director | Buy | 2,840,429 | $52.2M | Form 4, May 6, 2026 |
| May 6, 2026 | Rajeev M. Shah Director | Buy | 2,840,429 | $52.2M | Form 4, May 6, 2026 |
| May 6, 2026 | Capital Nexus Fund L.P. RA II Director | Buy | 2,840,429 | $52.2M | Form 4, May 6, 2026 |
| May 6, 2026 | Capital Nexus Fund L.P. RA IV Director | Buy | 2,840,429 | $52.2M | Form 4, May 6, 2026 |
| May 6, 2026 | Capital Healthcare Fund LP RA Director | Buy | 2,840,429 | $52.2M | Form 4, May 6, 2026 |
| May 6, 2026 | Capital Management L.P. Ra Director | Buy | 2,840,429 | $52.2M | Form 4, May 6, 2026 |
Recent 8-K events
- 8-K filed 2026-11-10
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-09-24
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-08-11
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-21
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-05-11
- Item 5.02 Departure or appointment of directors or officers; compensation
- 8-K filed 2026-05-04
- Item 5.03 Amendments to articles or bylaws; change in fiscal year
- Item 8.01 Other events
Frequently asked questions about Hemab Therapeutics Holdings, Inc.
- What does Hemab Therapeutics Holdings, Inc. do?
- In its own words, from Item 1 of its 10-K: "Hemab is pioneering the first preventative treatments and functional cures for patients with rare bleeding and thrombotic disorders."
- Where is Hemab Therapeutics Holdings, Inc. headquartered?
- Cambridge, MA.
- What is Hemab Therapeutics Holdings, Inc.'s stock ticker?
- COAG on Nasdaq.
- What industry is Hemab Therapeutics Holdings, Inc. in?
- Biological Products, (No Diagnostic Substances), SIC code 2836.
- What is Hemab Therapeutics Holdings, Inc.'s website?
- hemab.com. Investor relations: https://ir.hemab.com/.
- When does Hemab Therapeutics Holdings, Inc. report earnings next?
- January 31, 2027. This is an estimate from past filing dates, not a confirmed date.
- Is Hemab Therapeutics Holdings, Inc. a public company?
- Yes. Hemab Therapeutics Holdings, Inc. files with the SEC under CIK 0002114044 and trades as COAG.
- How many shares of Hemab Therapeutics Holdings, Inc. are outstanding?
- 46.7 million shares as of October 30, 2026, from its 10-Q filed November 10, 2026.
- How many business segments does Hemab Therapeutics Holdings, Inc. report?
- 1 reportable segment for the period ending September 30, 2026, from its 10-Q filed November 10, 2026.
- Have Hemab Therapeutics Holdings, Inc. insiders traded stock recently?
- Since May 6, 2026, officers and directors reported 0 open-market sales and 6 purchases worth about $313M on Forms 4 and 5. The most recent: Peter Kolchinsky (Director) bought 2,840,429 shares on May 6, 2026.